Cargando…

Online Prostate-Specific Membrane Antigen and Positron Emission Tomography–Guided Radiation Therapy for Oligometastatic Prostate Cancer

PURPOSE: Stereotactic ablative radiation therapy (SABR) for oligometastatic prostate cancer (OMPC) may improve clinical outcomes, but current challenges in intrafraction tracking of multiple small targets limits treatment accuracy. A biology-guided radiation therapy (BgRT) delivery system incorporat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hrinivich, William T., Phillips, Ryan, Da Silva, Angela J., Radwan, Noura, Gorin, Michael A., Rowe, Steven P., Pienta, Kenneth J., Pomper, Martin G., Wong, John, Tran, Phuoc T., Kang-Hsin Wang, Ken
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Physics Contribution
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136645/ https://www.ncbi.nlm.nih.gov/pubmed/32280826 http://dx.doi.org/10.1016/j.adro.2019.10.006

Ejemplares similares

Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted (18)F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern
por: Yin, Yafu, et al.
Publicado: (2019)

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)
por: Radwan, Noura, et al.
Publicado: (2017)

A Voice From the Past: Rediscovering the Virchow Node With Prostate-specific Membrane Antigen-targeted (18)F-DCFPyL Positron Emission Tomography Imaging
por: Werner, Rudolf A., et al.
Publicado: (2018)

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial
por: Phillips, Ryan, et al.
Publicado: (2020)

Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT
por: Phillips, Ryan M., et al.
Publicado: (2017)

Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma
por: Udovicich, Cristian, et al.
Publicado: (2022)

Uptake of prostate-specific membrane antigen-targeted (18)F-DCFPyL in avascular necrosis of the femoral head
por: Torga, Gonzalo, et al.
Publicado: (2019)

A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)
por: Hasan, Hamza, et al.
Publicado: (2020)

Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience
por: Deek, Matthew P., et al.
Publicado: (2019)

Prostate-specific membrane antigen (PSMA) imaging: the past is prologue and the future is scintillating
por: Rowe, Steven P., et al.
Publicado: (2020)

Oligometastatic Prostate Cancer to the Navicular Bone: Case Report
por: Reyes, Diane K., et al.
Publicado: (2015)

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [(18)F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation
por: Shenderov, Eugene, et al.
Publicado: (2017)

Altering the Natural History of Oligometastatic Prostate Cancer With Local Therapies: Reality Versus Illusion
por: Tran, Phuoc T., et al.
Publicado: (2017)

Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer
por: Reyes, D. K., et al.
Publicado: (2020)

Oligometastatic Prostate Cancer Treated with Metastasis-Directed Therapy Guided by Positron Emission Tomography: Does the Tracer Matter?
por: Lanfranchi, Francesco, et al.
Publicado: (2023)

CT‐based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration‐naïve oligometastatic prostate cancer
por: Sheikhbahaei, Sara, et al.
Publicado: (2020)

A Pilot Trial of Pembrolizumab plus Prostatic Cryotherapy for Men with Newly Diagnosed Oligometastatic Hormone-Sensitive Prostate Cancer
por: Ross, Ashley E., et al.
Publicado: (2019)

Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
por: Plichta, Kristin A., et al.
Publicado: (2021)

Oligometastatic Prostate Cancer
por: Stevens, Daniel J., et al.
Publicado: (2016)

Patterns of recurrence and modes of progression after metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer
por: Deek, Matthew P., et al.
Publicado: (2020)

Association of True Positivity with Serum Prostate-Specific Antigen Levels and Other Clinical Factors in Indeterminate PSMA-RADS-3A Lesions Identified on (18)F-DCFPyL PET/CT Scans
por: Garg, Tushar, et al.
Publicado: (2022)

Prostate-specific membrane antigen (PSMA)–ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer
por: Tateishi, Ukihide
Publicado: (2020)

Role of surgery in oligometastatic prostate cancer
por: Jenjitranant, Pocharapong, et al.
Publicado: (2019)

Brachytherapy for oligometastatic prostate cancer to the penis
por: Martz, Nicolas, et al.
Publicado: (2021)

(177)Lu‐PSMA radioligand therapy effectiveness in metastatic castration‐resistant prostate cancer: An updated systematic review and meta‐analysis
por: Sadaghiani, Mohammad S., et al.
Publicado: (2022)

Positron Emission Tomographic Imaging in Stroke: Cross-Sectional and Follow-Up Assessment of Amyloid in Ischemic Stroke
por: Sahathevan, Ramesh, et al.
Publicado: (2016)

Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted (18)F-DCFPyL in peripheral ganglia
por: Werner, Rudolf A., et al.
Publicado: (2017)

PSMA-targeted [(18)F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework
por: Reyes, Diane K., et al.
Publicado: (2019)

Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen
por: Inubushi, Masayuki, et al.
Publicado: (2020)

Making the Case for Prostate-Specific Membrane Antigen-Targeted Positron Emission Tomography/Computed Tomography in Suspected Prostate Cancer
por: Singh, Harmandeep
Publicado: (2020)

Risk of Tumor Upstaging With Prostate-Specific Membrane Antigen Positron Emission Tomography in Patients With High-Risk Prostate Cancer
por: Brant, Aaron, et al.
Publicado: (2022)

The biology and treatment of oligometastatic cancer
por: Reyes, Diane K., et al.
Publicado: (2015)

Oligometastatic prostate cancer: Metastases-directed therapy?
por: Van Poppel, Hein, et al.
Publicado: (2016)

Oligometastatic prostate cancer: Reality or figment of imagination?
por: Foster, Corey C., et al.
Publicado: (2018)

Imaging modalities in synchronous oligometastatic prostate cancer
por: Futterer, Jurgen J., et al.
Publicado: (2018)

Stereotactic ablative radiotherapy for oligometastatic prostate cancer
por: Gallizia, Elena, et al.
Publicado: (2022)

Oligometastatic carcinoma prostate – An overview of the last decade
por: Shah, Milap J, et al.
Publicado: (2023)

Metastatic superscan in prostate carcinoma on gallium-68-prostate-specific membrane antigen positron emission tomography/computed tomography scan
por: Agarwal, Krishan Kant, et al.
Publicado: (2016)

Fluorodeoxyglucose, sodium fluoride, and prostate-specific membrane antigen positron emission tomography studies for treatment response assessment in prostate cancer
por: Sarikaya, Ismet, et al.
Publicado: (2018)

Upcoming Role of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Detecting Occult Metastases in Prostate Cancer
por: Gupta, Parul, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qngdfatb5tv8djpaju2q6g02t9